logo
  

Roche To Launch Short Duration Infusion Gazyvaro For Patients In The EU - Quick Facts

Roche (RHHBY) reported EMA approval of a shorter 90-minute Gazyvaro infusion time, administered in combination with chemotherapy in patients with previously treated or untreated advanced follicular lymphoma. The regular rate of infusion can take approximately three to four hours, the company noted.

Levi Garraway, Chief Medical Officer, said: "Reducing the amount of time patients need to be in hospital has the potential to improve their treatment experience whilst also increasing efficiency for institutions and healthcare systems."

Following the approval, Gazyvaro's label update is being implemented immediately. Also, Roche is planning to launch short duration infusion Gazyvaro for patients in the EU with previously treated and untreated advanced follicular lymphoma as soon as possible.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sandoz, Inc., an unit of Novartis AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high temperatures that may have impacted product effectiveness, the U.S. Food and Drug Administration or FDA said in a statement. Livia Global, Inc., a health and wellness company, is recalling two lots of its Liviaone liquid probiotics citing the possibility of contamination by Pseudomonas aeruginosa, the U.S. Food and Drug Administration said. Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause life-threatening infection in immunocompromised individuals. United Airlines operated Thursday the first ever passenger flight using 100% Sustainable Aviation Fuel or SAF as part of its efforts to combat climate change. The airline flew the green flight from Chicago's O'Hare International Airport or ORD to Washington, D.C.'s Reagan National Airport or DCA with more than 100 passengers.
Follow RTT